Cargando…

Immunomodulatory Agents for Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Minařík, Jiří, Ševčíková, Sabina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739922/ https://www.ncbi.nlm.nih.gov/pubmed/36497241 http://dx.doi.org/10.3390/cancers14235759

Ejemplares similares

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma
por: Dementyeva, Elena, et al.
Publicado: (2013)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Identification of patients at high risk of secondary extramedullary multiple myeloma development
por: Stork, Martin, et al.
Publicado: (2021)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Long Non-Coding RNAs in Multiple Myeloma
por: Butova, Romana, et al.
Publicado: (2019)

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma
por: Vlachová, Monika, et al.
Publicado: (2022)

Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma
por: Kubiczkova, Lenka, et al.
Publicado: (2014)

Latent tuberculosis and the use of immunomodulatory agents
por: Aguiar, Fábio Silva, et al.
Publicado: (2019)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
por: Patel, Urmeel H., et al.
Publicado: (2015)

Adherence to immunomodulatory drugs in patients with multiple myeloma
por: Cransac, Amélie, et al.
Publicado: (2019)

MicroRNAs in urine are not biomarkers of multiple myeloma
por: Sedlaříková, Lenka, et al.
Publicado: (2015)

Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease
por: Abdallah, Al‐Ola, et al.
Publicado: (2021)

Mechanistic Studies and a Retrospective Cohort Study: The Interaction between PPAR Agonists and Immunomodulatory Agents in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2022)

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma
por: Chen, Lucia Y., et al.
Publicado: (2022)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma
por: Minarik, Jiri, et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma
por: Swan, Dawn, et al.
Publicado: (2020)

Centrosome associated genes pattern for risk sub-stratification in multiple myeloma
por: Kryukov, Fedor, et al.
Publicado: (2016)

Dynamics of tumor‐specific cfDNA in response to therapy in multiple myeloma patients
por: Vrabel, David, et al.
Publicado: (2019)

Prognostic Value of Hepatocyte Growth Factor, Syndecan-1, and Osteopontin in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
por: Minarik, Jiri, et al.
Publicado: (2012)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation or Treated with Immunomodulatory Agents.
por: Khalafallah, Alhossain, et al.
Publicado: (2010)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Development of oral immunomodulatory agents in the management of multiple sclerosis
por: Nicholas, Richard, et al.
Publicado: (2011)

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
por: Bútová, Romana, et al.
Publicado: (2021)

Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
por: Hideshima, T, et al.
Publicado: (2015)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients
por: Byun, Ja Min, et al.
Publicado: (2018)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience
por: Krejci, Marta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6dhs3aqebp9c4u6b7kouhcfih2